Evidence map›Paper›PMID 40895170›Full record

ArticleClinical parkinsonism & related disorders2025

Safety and Feasibility of Serial Lumbar Punctures: Long-term Results from the Parkinson's Progression Markers Initiative.

William Barbosa, Ruth B Schneider, Seung Ho Choi, Micah J Marshall, David-Erick Lafontant, Chelsea Caspell-Garcia, Christopher S Coffey, Jason Ross, Andrew Siderowf, Kenneth Marek and 2 more

Abstract read
In one paragraph

Article in Clinical parkinsonism & related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

William BarbosaUniversity of Rochester Medical Center, Rochester, NY, United States.
Ruth B SchneiderUniversity of Rochester Medical Center, Rochester, NY, United States.
Seung Ho ChoiUniversity of Iowa College of Public Health, Department of Biostatistics, Iowa City, IA, United States.
Micah J MarshallUniversity of Iowa College of Public Health, Department of Biostatistics, Iowa City, IA, United States.
David-Erick LafontantUniversity of Iowa College of Public Health, Department of Biostatistics, Iowa City, IA, United States.
Chelsea Caspell-GarciaUniversity of Iowa College of Public Health, Department of Biostatistics, Iowa City, IA, United States.
Christopher S CoffeyUniversity of Iowa College of Public Health, Department of Biostatistics, Iowa City, IA, United States.
Jason RossNorthwestern University Feinberg School of Medicine, Chicago, IL, United States.
Andrew SiderowfUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.
Kenneth MarekInstitute of Neurodegenerative Disorders, New Haven, CT, United States.
Tanya SimuniNorthwestern University Feinberg School of Medicine, Chicago, IL, United States.
Parkinson’s Progression Markers Initiative (PPMI)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cerebrospinal fluid (CSF) serves an essential role in biomarker research. New Parkinson's disease (PD) classifications incorporate CSF α-synuclein status into trial design. This study evaluated the safety and feasibility of serial CSF collection in participants enrolled in the Parkinson's Progression Markers Initiative (PPMI). Methods: PPMI participants were evaluated over 13-years with lumbar punctures (LPs) occurring annually from baseline through year five and biennially thereafter. Adverse events and compliance, defined as percentage of LPs with CSF collection, were assessed at baseline and upon follow up. Logistic regression and generalized linear mixed effects models were used to calculate odds ratios and 95% confidence intervals for predictors of baseline and longitudinal LP success. Results: 3479 participants (PD: n = 1412, prodromal: n = 1768, healthy control: n = 299) were analyzed. 3360 attempted at least one LP with 29.5 % experiencing an adverse event (1.3 % severe). Baseline compliance was 90 %. From baseline to year five, percent change in compliance decreased by 39.4 % in the PD cohort, 41.4 % in the prodromal cohort, and 27.8 % in the healthy control cohort. Predictive variables of baseline LP success included fewer years since diagnosis (PD: OR 0.82, 0.76-0.89), lower BMI (prodromal: OR 0.92, 0.89-0.94), and site location U.S. vs. non-U.S. (PD: OR 1.5, 1.03-2.18, healthy control: OR 3.6, 1.22-10.64). Baseline LP success was the best predictor of longitudinal success (OR 7.82, 5.74-10.65). Conclusions: Lumbar punctures were safe in PD research participants over a 13-year period. Compliance was high over the first three years, but further investigation is warranted to improve long term success.

Indexed as

Cerebrospinal fluidFeasibilityLumbar punctureParkinson’s diseaseα-synuclein

Identifiers

PMID40895170
PMCPMC12391599

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.